Charles E. Geyer, Jr, MD | Authors

Articles

Impact of Pertuzumab in HER2-Positive Breast Cancer

December 08, 2018

Charles E. Geyer, Jr, MD, professor of medicine at Virginia Commonwealth University School of Medicine, associate director for clinical research and Harrigan, Haw, Luck Families Chair in Cancer Research at Massey Cancer Center, discusses the impact of pertuzumab (Perjeta) in the treatment of patients with HER2-positive breast cancer at the 2018 San Antonio Breast Cancer Symposium.